You are here: Home » International » News » Markets
Business Standard

Pfizer stock falls as Covid pill fails in preventive therapy trial

The trial failure, along with reports of rebounding coronavirus levels in some patients who have completed a course of Paxlovid, are unlikely to change the drug's sales potential

Topics
Pfizer | Coronavirus Vaccine | clinical trials

Bloomberg 

Paxlovid
Compared with those who took a placebo, people who received Paxlovid had about a third less risk of infection, which wasn’t statistically significant. | Photo: Bloomberg

Inc. slumped after Paxlovid, its pill for treating Covid-19, failed to show benefit as a preventive therapy in a trial.

Paxlovid is poised to become one of the fastest-selling drugs of all time, with $24 billion in projected 2022 sales, according to analytics group Airfinity Ltd. has also reaped billions in global sales from its Covid-19 vaccine.

The company said late Friday that the drug failed to hit its main goal of reducing the risk that adults exposed to the coronavirus through contact with a household member would become infected. Compared with those who took a placebo, people who received Paxlovid had about a third less risk of infection, which wasn’t statistically significant.

The shares fell 2.2 per cent at 9:36 a.m. in New York. They had declined 17 per cent this year through Friday’s close.

The trial failure, along with reports of rebounding coronavirus levels in some patients who have completed a course of Paxlovid, are unlikely to change the drug’s sales potential, according to Bloomberg Intelligence analysts John Murphy and Sam Fazeli.

“The trial miss at most takes away a small incremental sales opportunity in future years,” they said Monday in a research note. The reports of rebound infections are “also not surprising as viral dynamics during an infection are unlikely to fit perfectly with a rigid 5-day course.”

Morgan Stanley analysts, who had estimated the drug’s sales to reach $48 billion in 2022, said the prophylaxis data might affect their forecast.

“The addressable opportunity for the drug is more limited, which could impact government contracting decisions and hence we see downside risk to our Paxlovid estimates,” according to a note from Terence Flynn. “Our recent investor conversations suggested measured expectations for an upgrade” to Pfizer’s Paxlovid guidance.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, May 03 2022. 10:42 IST
RECOMMENDED FOR YOU
.